News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) Announces Launch of Antiepileptic Agent Inovelon® Tablets 100 mg, 200 mg in Japan


6/19/2013 10:13:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Tokyo, May 28, 2013 (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch antiepileptic agent Inovelon(R) Tablets 100 mg and 200 mg (rufinamide) in Japan on May 29 as an adjunctive therapy to other antiepileptic drugs (AEDs) in the treatment of Lennox-Gastaut syndrome (LGS). The agent was designated by the Japanese Ministry of Health, Labour and Welfare (MHLW) as an orphan drug in June 2011; it received Japan manufacturing and marketing authorization on March 25, 2013, and was placed on the country's National Health Insurance (NHI) drug price list on May 24 of the same year.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES